 |
 Video: What is a Stock Split?
|
|
|
| Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. JAKAFI (ruxolitinib) is Co.'s initial product approved by the U.S. Food and Drug Administration for the treatment of adults with intermediate or high-risk myelofibrosis, for the treatment of adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea, for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older and for the treatment of chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. According to our INCY split history records, Incyte has had 2 splits. | |
|
Incyte (INCY) has 2 splits in our INCY split history database. The first split for INCY took place on November 10, 1997. This was a 2 for 1
split, meaning for each share of INCY owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split. INCY's second split took place on September 01, 2000. This was a 2 for 1 split, meaning for each share of INCY owned pre-split, the shareholder now owned 2 shares. For example, a 2000 share position pre-split, became a 4000 share position following the split.
When a company such as Incyte splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the INCY split history from start to finish, an original position size of 1000 shares would have turned into 4000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Incyte shares, starting with a $10,000 purchase of INCY, presented on a split-history-adjusted basis factoring in the complete INCY split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
10/07/2014 |
|
| End date: |
10/03/2024 |
|
| Start price/share: |
$46.76 |
|
| End price/share: |
$67.04 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
43.37% |
|
| Average Annual Total Return: |
3.67% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$14,337.98 |
|
| Years: |
10.00 |
|
|
|
| Date |
Ratio |
| 11/10/1997 | 2 for 1
| | 09/01/2000 | 2 for 1 |
|
|
Free INCY Email Alerts:
